RxDoctor Payments Data

Veronica Kon Graversen, MD

Retina Specialist · Fort Myers, FLNPI 1467773838

Payments from drug & device makers

$1,164in general payments, 2019–2025

Across 18 payments — averaging $64.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Apellis Pharmaceuticals, Inc.$427
  • Dutch Ophthalmic, USA$228
  • Astellas Pharma US Inc$125
  • Alcon$111
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$108
  • Mallinckrodt Hospital Products Inc.$60
  • plus $106 from 3 others

What the payments were for

  • Food & beverage$1,14799%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,164 in reported general payments places this provider in the 25th percentile of 118 retina specialist providers in Florida.

See all retina specialist providers in Florida

Medicare billing

Part B allowed, 2024
$6,401,509
Medicare patients
2,225
Services billed
72,999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate329$14,470
LumiganBimatoprost13$5,819
CombiganBrimonidine Tartrate/Timolol11$4,768
SimbrinzaBrinzolamide/Brimonidine Tart18$4,192
Ketorolac Tromethamine238$4,191
Cyclosporine12$3,576
Difluprednate20$2,179
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat153$1,966
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$1,659
Fluorometholone24$1,615
Latanoprost141$1,268
Tobramycin-DexamethasoneTobramycin/Dexamethasone29$1,112
Dorzolamide Hcl71$1,016
Brimonidine Tartrate123$793
Tobramycin145$759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$49$10,58724 claims
AlconSimbrinza$111$4,19218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 118 retina specialist providers in Florida.

Other retina specialist in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →